Valuation: Assembly Biosciences, Inc.

Market Cap 69Cr 59Cr 55Cr 51Cr 95Cr 6.59TCr 97Cr 651.21Cr 255Cr 3.3TCr 258.71Cr 253.08Cr 11TCr P/E 2026 *
-59x
P/E 2027 * -11.6x
Enterprise Value 69Cr 59Cr 55Cr 51Cr 95Cr 6.59TCr 97Cr 651.21Cr 255Cr 3.3TCr 258.71Cr 253.08Cr 11TCr EV / Sales 2026 *
11.1x
EV / Sales 2027 * 21.4x
Free-Float
72.34%
Yield 2026 *
-
Yield 2027 * -
1 day+5.32%
1 week+25.06%
Current month+34.77%
1 month+26.22%
3 months+27.60%
6 months+30.30%
Current year-0.50%
1 week 29.78
Extreme 29.785
34.57
1 month 24.5
Extreme 24.5
34.57
Current year 21.8
Extreme 21.795
34.68
1 year 20.23
Extreme 20.23
39.7
3 years 7.69
Extreme 7.692003
39.7
5 years 7.69
Extreme 7.692003
47.28
10 years 7.69
Extreme 7.692003
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 04/06/2026
Director/Board Member 61 14/12/2017
Director/Board Member 68 06/08/2019
Date Insider Type Main position Quantity % Market Cap.
04/06/26 Free

Director

8,000 0.0514%
29/03/26 Free

Chief Technology Officer

26,000 0.1671%
08/08/25 BuyCompany 45,91,840 72.2409%
Change 5-day change 1-year change 3-year change Capi.($)
+5.32%+25.06%+34.18%+203.23% 69Cr
+2.37%+2.30%+3.39%+22.74% 5.05TCr
-0.62%+4.58%+487.47%+624.71% 4.6TCr
+2.09%+4.96%+20.59%+95.21% 4.28TCr
+3.85%+3.13%+29.60%+16.50% 4.1TCr
-0.72%-3.91%+17.87%+47.98% 3.2TCr
+3.04%+1.89%+31.62%+143.62% 1.7TCr
+4.33%+1.63% - - 1.71TCr
+1.44%+1.52%+4.22%+31.00% 1.43TCr
+3.87%+1.98%+82.99%+45.80% 1.38TCr
Average +2.50%+4.31%+79.10%+136.75% 2.75TCr
Weighted average by Cap. +1.89%+2.43%+104.71%+154.28%

Financials

2026 *2027 *
Net sales 6.2Cr 5.32Cr 4.97Cr 4.56Cr 8.57Cr 592.79Cr 8.71Cr 59Cr 23Cr 297.31Cr 23Cr 23Cr 982.99Cr 3.22Cr 2.77Cr 2.58Cr 2.37Cr 4.46Cr 308.25Cr 4.53Cr 30Cr 12Cr 154.6Cr 12Cr 12Cr 511.15Cr
Net income -1.06Cr -91.03L -85L -77.98L -1.47Cr -101.43Cr -1.49Cr -10Cr -3.93Cr -51Cr -3.98Cr -3.9Cr -168.19Cr -6.03Cr -5.17Cr -4.83Cr -4.43Cr -8.33Cr -576.01Cr -8.47Cr -57Cr -22Cr -288.89Cr -23Cr -22Cr -955.17Cr
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
19/26/19 $33.84 +5.32% 3,84,565
18/26/18 $32.13 +7.06% 4,84,813
17/26/17 $30.01 -8.92% 3,04,523
14/26/14 $32.95 +10.02% 5,59,108
13/26/13 $29.95 +10.68% 7,29,236
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
33.84USD
Average target price
50.00USD
Spread / Average Target
+47.75%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock